Home » Stocks » NRIX

Nurix Therapeutics, Inc. (NRIX)

Stock Price: $27.12 USD 0.95 (3.63%)
Updated May 11, 2021 4:00 PM EDT - Market closed
Market Cap 1.09B
Revenue (ttm) 19.97M
Net Income (ttm) n/a
Shares Out 44.35M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 11
Last Price $27.12
Previous Close $26.17
Change ($) 0.95
Change (%) 3.63%
Day's Open 25.28
Day's Range 24.63 - 27.88
Day's Volume 270,008
52-Week Range 15.21 - 52.38

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

On track to initiate Phase 1 trials for four wholly owned drug candidates in 2021

4 weeks ago - GlobeNewsWire

SAN FRANCISCO, April 07, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands,...

1 month ago - GlobeNewsWire

Research focused on targeted degradation of MYCN for the potential treatment of neuroblastoma and medulloblastoma Program is one of four in Alex's Lemonade Stand Foundation-funded $18.5 million Crazy 8 ...

1 month ago - GlobeNewsWire

CBL-B inhibitor NX-1607 mediates anti-tumor activity through both T cells and NK cells Preclinical tumor models support clinical development of NX-1607 as monotherapy or in combination with PD-1 blockade

2 months ago - GlobeNewsWire

SAN FRANCISCO, March 09, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the closing of its un...

2 months ago - GlobeNewsWire

SAN FRANCISCO, March 09, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur Sands, M....

2 months ago - GlobeNewsWire

SAN FRANCISCO, March 04, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the pricing of its un...

2 months ago - GlobeNewsWire

SAN FRANCISCO, March 02, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it has commenced...

2 months ago - GlobeNewsWire

First Investigational New Drug (IND) application cleared for NX-2127 in patients with relapsed and refractory B-cell malignancies

2 months ago - GlobeNewsWire

Expansion of agreement results in an additional payment of $22 million to Nurix Expansion of agreement results in an additional payment of $22 million to Nurix

4 months ago - GlobeNewsWire

Data support a planned clinical trial of NX-2127 in B-cell malignancies Data support a planned clinical trial of NX-2127 in B-cell malignancies

5 months ago - GlobeNewsWire

SAN FRANCISCO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.  (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it will be prese...

6 months ago - GlobeNewsWire

SAN FRANCISCO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it will present d...

6 months ago - GlobeNewsWire

SAN FRANCISCO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), today announced that, based on his desire to lead Nurix's Scientific Advisory Board, Robert Tjian, Ph.D. has res...

6 months ago - GlobeNewsWire

Completed recent IPO raising approximately $238 .5 million in gross proceeds

6 months ago - GlobeNewsWire

SAN FRANCISCO, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., (NASDAQ: NRIX), a company developing targeted protein modulation drugs, today announced the Company will be presenting at the 3...

7 months ago - GlobeNewsWire

Nurix Therapeutics Inc. shares nrix fell 2.3% in their trading debut Friday, after pricing above the proposed price range.

9 months ago - Market Watch

About NRIX

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader with immunomodulatory drug (IMiD) activity for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader without IMiD activity for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally ava... [Read more...]

Industry
Biotechnology
IPO Date
Jul 24, 2020
Stock Exchange
NASDAQ
Ticker Symbol
NRIX
Full Company Profile

Financial Performance

In 2020, NRIX's revenue was $17.82 million, a decrease of -42.73% compared to the previous year's $31.12 million. Losses were -$43.24 million, 99.3% more than in 2019.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for NRIX stock is "Buy." The 12-month stock price forecast is 49.00, which is an increase of 80.68% from the latest price.

Price Target
$49.00
(80.68% upside)
Analyst Consensus: Buy